← Back to headlines
Relmada Plans NDV-01 IND Submission by End of 2026, Extends Cash Runway Through 2029
Relmada Therapeutics announced its intention to submit an Investigational New Drug (IND) application for NDV-01 by the end of 2026, with its cash reserves projected to last through 2029.
7 Aug, 08:55 — 7 Aug, 08:55
Sources
Showing 1 of 1 sources
